期刊
COMPLEMENTARY THERAPIES IN MEDICINE
卷 44, 期 -, 页码 296-300出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ctim.2019.05.010
关键词
Vaccinium arctostaphylos; Hypertension; Obesity; Clinical trial
资金
- Research Institute for Islamic and Complementary Medicine affiliated to the Iran University of Medical Sciences [2937]
Objectives: To evaluate the antihypertensive efficacy and safety of a standardized Vaccinium arctostaphylos (V. arctostaphylos) berry hydro-alcoholic extract in the overweight/obese hypertensive patients. Design: Randomized placebo-controlled trial. Setting: Baqiyatallah hospital (Tehran, Iran). Interventions: The antihypertensive efficacy and safety of 3-month intake of 400 mg extract capsule three times daily alongside standardized anti-hypertensive regimen in the treatment of 50 patients was compared with the placebo (n = 50). Main outcome measures: SBP (systolic blood pressure), DBP (diastolic blood pressure), body mass index, waist circumference, CBC (complete blood count), blood levels of AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), BUN (blood urea nitrogen) and creatinine. Results: SBP decreased from 152.1 +/- 7.7 to 140.5 +/- 10.7 in the V. arctostaphylos group and from 152.9 +/- 8.1 to 150.8 +/- 9.3 in the placebo group (P < 0.001). DBP decreased from 90.3 +/- 8 to 82.1 +/- 8.8 in the V. arctostaphylos group and from 89.6 +/- 7.8 to 87.6 +/- 7.9 in the placebo group (P < 0.001). The extract capsule had no significant effect on the other parameters (P > 0.05). Moreover, no drug side effect and adverse interaction with other antihypertensive drugs was observed in the patients. Conclusions: V. arctostaphylosberry extract improves blood pressure control and has safety and tolerability in the overweight/obese hypertensive patients taking standard antihypertensive drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据